GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV/Hib
- Conditions
- Hepatitis B
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 350
- Registration Number
- NCT00356564
- Locations
- 🇩🇪
GSK Investigational Site, Hamburg, Germany
Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 75
- Registration Number
- NCT00356603
- Locations
- 🇯🇵
GSK Investigational Site, Tokyo, Japan
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2014-07-21
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 57
- Registration Number
- NCT00356811
- Locations
- 🇷🇺
GSK Investigational Site, St. Petersburg, Russian Federation
Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: GW842470XDrug: Placebo
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2017-09-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 45
- Registration Number
- NCT00356642
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Mencevax™ ACWYBiological: meningococcal ACWY (vaccine)
- First Posted Date
- 2006-07-26
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00356369
- Locations
- 🇸🇦
GSK Investigational Site, Riyadh, Saudi Arabia
Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome
- First Posted Date
- 2006-07-24
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 450
- Registration Number
- NCT00355641
- Locations
- 🇨🇦
GSK Investigational Site, Regina, Saskatchewan, Canada
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Salmeterol 50 mcg BIDDrug: Fluticasone Propionate/Salmeterol 250/50 mcg BIDDevice: DISKUS inhaler
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 186
- Registration Number
- NCT00355342
- Locations
- 🇺🇸
GSK Investigational Site, Spokane, Washington, United States
Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy
- Conditions
- Epilepsy, Partial
- Interventions
- Drug: lamotrigine, 300 mg/dayDrug: lamotrigine, 250 mg/day
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 226
- Registration Number
- NCT00355082
- Locations
- 🇺🇦
GSK Investigational Site, Zaporizhzhya, Ukraine
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis
- Conditions
- Atopic DermatitisDermatitis, Atopic
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 190
- Registration Number
- NCT00354510
- Locations
- 🇳🇱
GSK Investigational Site, Utrecht, Netherlands
Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects
- Conditions
- Asthma
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2009-05-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT00354042